Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

Ge Qin(Sun Yat-sen University), Yanhong Deng(National Medical Products Administration)
Molecular Medicine
January 20, 2024
Cited by 18


Related Papers